Literature DB >> 33725354

Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Thuy Trang Nguyen1, Tuong Kha Vo2, Giau Van Vo3,4,5.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder in which the death of brain cells causes memory loss and cognitive decline. Existing drugs only suppress symptoms or delay further deterioration but do not address the cause of the disease. In spite of screening numerous drug candidates against various molecular targets of AD, only a few candidates, such as acetylcholinesterase inhibitors, are currently utilized as an effective clinical therapy. Currently, nano-based therapies can make a difference, providing new therapeutic options by helping drugs to cross the blood-brain barrier and enter the brain more effectively. The main aim of this review was to highlight advances in research on the development of nano-based therapeutics for improved treatment of AD.

Entities:  

Keywords:  Alzheimer’s disease; CNS; Molecular targets; Nanotherapeutic; Oxidative stress

Mesh:

Year:  2021        PMID: 33725354     DOI: 10.1007/978-3-030-55035-6_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  127 in total

Review 1.  Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 3.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

4.  APP processing and synaptic function.

Authors:  Flavio Kamenetz; Taisuke Tomita; Helen Hsieh; Guy Seabrook; David Borchelt; Takeshi Iwatsubo; Sangram Sisodia; Roberto Malinow
Journal:  Neuron       Date:  2003-03-27       Impact factor: 17.173

Review 5.  Epidemiology of Alzheimer disease.

Authors:  Christiane Reitz; Carol Brayne; Richard Mayeux
Journal:  Nat Rev Neurol       Date:  2011-02-08       Impact factor: 42.937

Review 6.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 7.  Alzheimer's disease: from pathology to therapeutic approaches.

Authors:  Roland Jakob-Roetne; Helmut Jacobsen
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 8.  Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.

Authors:  Shichun Tu; Shu-ichi Okamoto; Stuart A Lipton; Huaxi Xu
Journal:  Mol Neurodegener       Date:  2014-11-14       Impact factor: 14.195

Review 9.  Current advances in transdermal delivery of drugs for Alzheimer's disease.

Authors:  Thuy Trang Nguyen; Vo Van Giau; Tuong Kha Vo
Journal:  Indian J Pharmacol       Date:  2017 Mar-Apr       Impact factor: 1.200

Review 10.  Type 3 Diabetes and Its Role Implications in Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Qui Thanh Hoai Ta; Thi Kim Oanh Nguyen; Thi Thuy Dung Nguyen; Vo Van Giau
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

View more
  2 in total

Review 1.  Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders.

Authors:  Thuy Trang Nguyen; Thi Thuy Dung Nguyen; Nguyen-Minh-An Tran; Giau Van Vo
Journal:  Neurochem Res       Date:  2021-11-20       Impact factor: 3.996

Review 2.  Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems.

Authors:  Prashant Poudel; Soyeun Park
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.